类风湿性关节炎(RA)是人类的一种系统性自身免疫性疾病。利妥昔单抗(rituximab)作为一种针对B细胞特异性抗原CD20的人-鼠嵌合单克隆抗体,是首个以B细胞为靶标治疗RA的药物。根据美国类风湿学学会(ACR)20,50,70反应标准,甲氨蝶呤与利妥昔单抗联用能显著减轻类风湿因子血清阳性的RA的体征和症状,且比较安全。在一项双盲对照的Ⅱ期临床试验中,贝利单抗(belimumab)有较好的耐受性和良好的效应。 Rheumatoid arthritis (RA) is a systemic autoimmune disease in humans. Rituximab, the human-mouse chimeric monoclonal antibody directed against the B cell-specific antigen CD20, is the first drug to treat RA with B-cell targets. According to the American College of Rheumatology (ACR) 20, 50, and 70 response criteria, the combination of methotrexate and rituximab significantly reduced the signs and symptoms of rheumatoid factor seropositive RA and was relatively safe. In a double-blind, controlled phase II trial, belimumab had better tolerability and good effect.